The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in Vitro and affects antitumor activity in models of Hodgkin's disease

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3736-3742

  Wahl, Alan F ^a   Klussman, Kerry ^a   Thompson, Jennifer D ^a   Chen, Judy H ^a   Francisco, Leigh V ^a   Risdon, Grant ^a,b   Chace, Dana F ^a   Siegall, Clay B ^a   Francisco, Joseph A ^a  

^a SEATTLE GENETICS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 10; ANTINEOPLASTIC AGENT; CD30 ANTIBODY; CD30 ANTIGEN; CHIMERIC ANTIBODY; DNA FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; SGN 30; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD DISEASE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DISEASE MODEL; DNA STRUCTURE; DOSE RESPONSE; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN CONSTANT REGION; LYMPHOMA; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; RELAPSE; SCID MOUSE; SURVIVAL; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CELL CYCLE; CELL DIVISION; CHO CELLS; CRICETINAE; DNA FRAGMENTATION; HODGKIN DISEASE; HUMANS; HYBRIDOMAS; MICE; MICE, SCID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036645267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1
2. CD30 in normal and neoplastic cells
3. CD30+ T cells in rheumatoid synovitis: Mechanisms of recruitment and functional role
4. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis
5. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease
6. Expression of the CD30 antigen in non-lymphoid tissues and cells
7. Role for CD30 in HIV expression
8. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
9. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway
10. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes
11. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
12. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells
13. CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: Apoptosis or cell-cycle arrest?
14. Strength of CD30 signal determines sensitivity to apoptosis
15. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence
16. Response of refractory Hodgkin's disease to monoclonal anti-CD 30 immunotoxin
17. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
18. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system
19. Rituximab: The first monoclonal antibody approved for the treatment of lymphoma
20. Functional effects of CD30 on a large granular lymphoma cell line. YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation
21. Separation by counterflow elutriation and analysis of T and B lymphocytes in progressive stages of the cell division cycle
22. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments
23. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
24. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299
25. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice
26. Cancer statistics, 1999
27. Autologous hematopoietic cell transplantation in Hodgkin's disease
28. Anti-CD30 antibody-based therapy
29. Recombinant immunotoxins for the treatment of Hodgkin's disease
30. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis
31. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization
32. Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry